The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Under the deal, Quiver will receive an undisclosed advance payment and research support
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Subscribe To Our Newsletter & Stay Updated
